Press Releases

2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000

2002 Press Releases

Listed below are all of the QLT press releases available for the year you have selected.

December 17	QLT and Novartis Provide Update on Phase II Visudyne Studies	PDF version
November 21	QLT Streamlines Workforce and Refocuses on Key Development Activities to Ensure Continued Profitability and Growth	PDF version
October 22	QLT Announces Q3 Results for 2002 and Reiterates Guidance	PDF version
October 21	Long-Term Benefit of Visudyne® Therapy for Wet Age-Related Macular Degeneration Published in Archives of Ophthalmology	PDF version
October 17	QLT Announces Visudyne® Sales for Third Quarter of 2002	PDF version
October 11	QLT and Novartis Ophthalmics Launch Phase III Program to Treat Skin Cancer	PDF version
October 3	QLT Receives FDA Fast Track Status for Tariquidar	PDF version
September 24	QLT Announces Favorable Court Decision in Massachusetts Eye and Ear Infirmary (MEEI) Litigation	PDF version
August 28	Visudyne® Approved for Occult Subfoveal Choroidal Neovascularisation (CNV) Secondary to Age-Related Macular Degeneration (AMD)	PDF version
August 27	QLT and Novartis Ophthalmics Reach Key Milestone in their Comprehensive Clinical Trial Program for Visudyne®	PDF version
July 25	QLT Announces Q2 Results for 2002 and Reiterates Guidance	PDF version
July 22	QLT Announces Visudyne® Sales for Second Quarter of 2002	PDF version
June 28	QLT Begins Pivotal Phase III Clinical Programs for Multi-Drug Resistance in Non-Small Cell Lung Cancer Patients	PDF version
May 31	QLT and Novartis Ophthalmics Announce Positive Recommendations for Visudyne® Approval in Europe From European Committee for Proprietary Medicinal Products	PDF version
May 28	Bill Newell Named Senior VP and Chief Business Officer of QLT	PDF version
May 21	Tariquidar, QLT's Late Stage Cancer Compound, Shows Advantages Over Previous Generations of P-GP Inhibitors	PDF version
April 23	QLT Announces Q1 Results for 2002 and Updates Guidance	PDF version
April 23	Novartis Ophthalmics and QLT Announce New Drug Application for Visudyne® in Japan	PDF version
April 23	Early Detection is Key to Maximizing Vision Outcomes in Age-Related Macular Degeneration	PDF version
April 16	QLT Announces Visudyne® Sales for First Quarter of 2002	PDF version
April 11	QLT Reduces Stock Option Request to Shareholders	PDF version
April 1	QLT Updates Status of Visudyne® Therapy Reimbursement in U.S.	PDF version
March 11	QLT Renews Shareholder Rights Plan	PDF version
February 6	QLT Announces Year-End Results for 2001 and Provides Guidance for 2002	PDF version

Visudyne® is a registered trademark of Novartis AG

Vancouver Web Design by Graphically Speaking